Lasa Supergenerics
12.04
+0.57(+4.97%)
Market Cap₹60.32 Cr
PE Ratio-1.60
IndustryHealthcare
Company Performance:
1D+4.97%
1M+21.37%
6M+0.67%
1Y-56.97%
5Y-86.05%
View Company Insightsright
More news about Lasa Supergenerics
05Aug 25
LASA Supergenerics Bolsters Board with Four New Independent Directors
Lasa Supergenerics Limited has appointed four new Additional Directors as Non-Executive Independent Directors for a five-year term starting August 05, 2025. The new directors are Mr. Ketan Bhau Songal (Agro-Veterinary Sciences expert), Mr. Pravin Gadalya Lachake (Poultry operations specialist), Mr. Yogesh Hari Ughada (Animal care professional), and Mrs. Rekha Hemant Wakh (Animal Nutrition specialist). These appointments aim to enhance the company's leadership and bring diverse expertise in veterinary sciences, poultry operations, animal care, and nutrition to its governance structure. The appointments are subject to shareholder approval and comply with SEBI regulations.
Lasa Supergenerics
12.04
+0.57
(+4.97%)
1 Year Returns:-56.97%
Industry Peers
Sun Pharmaceutical
1,782.60
(+1.27%)
Divis Laboratories
6,642.50
(0.0%)
Torrent Pharmaceuticals
4,092.20
(+3.95%)
Cipla
1,467.90
(-4.11%)
Dr Reddys Laboratories
1,242.80
(-1.07%)
Lupin
2,214.30
(+3.01%)
Mankind Pharma
2,311.80
(+3.17%)
Zydus Life Science
927.55
(-0.38%)
Aurobindo Pharma
1,235.40
(+0.33%)
Alkem Laboratories
5,806.50
(+2.67%)